Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1684 | HLX70 Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a double-blinded, placebo-controlled parallel, phase II clinical efficacy study evaluating Nitric Oxide Nasal Irrigation (NONI) for the treatment of COVID-19 in individuals with mild COVID-19 Infection.
Description: Measure the SARS-CoV-2 viral load (Cycle threshold) at baseline through Day 6 between NONI and control arms.
Measure: To Measure the efficacy of NONI compared to saline placebo control to shorten the duration of COVID-19 viral infectivity Time: 6 DaysDescription: Measure the proportion of subjects reaching Ct threshold (ie: unmeasurable viral load) between NONI and control
Measure: To Measure the virucidal effect of NONI compared to placebo in the nasal cavity in subjects with mild COVID-19 infection Time: 2, 4 and 6 daysDescription: Measure the difference in time-to Ct threshold (ie: unmeasurable viral load) between NONI and control.
Measure: To Measure the virucidal effect of NONI compared to placebo in the nasal cavity in subjects with mild COVID-19 infection Time: 2, 4 and 6 daysDescription: Measure the proportion of subjects requiring hospitalization or ER/ED visits for COVID-19/flu-like symptoms
Measure: To Measure the efficacy of NONI in prevention of progression of COVID-19 Time: 28 daysDescription: Measure the difference in 12-point COVID Symptom PROs score 0-3 (min 0 & max 36) and a QoL score from 0-100 (lower is worse) from baseline between NONI and control arms.
Measure: To measure reduction of patient reported outcome (PRO) of clinical cold score symptoms and quality of life (QoL) in subjects with COVID-19 Time: 6 daysDescription: Measure the difference in proportion of subjects experiencing a reduction of ≥ 5 from baseline between NONI and control arms.
Measure: To measure reduction of patient reported outcome (PRO) of clinical cold score symptoms and quality of life in subjects with COVID-19 Time: 2, 4, 6, 14 and 28 daysDescription: Measure the difference in proportion of subjects with reduction to a score of zero from baseline between NONI and control arms.
Measure: To measure reduction of patient reported outcome (PRO) of clinical cold score symptoms and quality of life in subjects with COVID-19 Time: 2, 4, 6, 14 and 28 daysDescription: Number of participants lost-to-follow-up,discontinuing study treatment or number of treatments due to intolerance
Measure: To measure the tolerance of NONI compared to saline placebo in participants with mild COVID-19 infection Time: 14 daysDescription: Severity and frequency of adverse events, pain, discomfort or discontinuations of treatment.
Measure: To measure the tolerance of NONI compared to saline placebo in participants with mild COVID-19 infection Time: 14 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports